What's breaking now, across thousands of outlets.
In the latest in a string of setbacks in biopharma’s efforts to fight Medicare drug price negotiations, a lawsuit from the industry’s top lobbying group has been rejected at the appeals level.
We haven't written up this one. Fierce Healthcare has the full story — the link below goes straight to it.
The study looked at high-risk Maven members with hypertension or diabetes, compared to CDC data.
In this edition of STAT Health Tech: CMS plans a launch event for Medicare chronic care pilot, and what the Meta settlement means for health AI.
In this GEN webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or complementary mechanisms.
The Phase I dose escalation trial of ACESOT-1051 (NCT06260514) will accelerate its patient enrollment, with Aprea planning to more than triple its number of active clinical sites for the study from…
The pharma industry has suffered a definitive loss in its legal battle against Medicare negotiations. The Fifth Circuit Court of Appeals on Wednesday rejected a challenge brought by the industry trade…
